Patients receive filgrastim subcutaneously (SC) or intravenously (IV) on days 1-7, fludarabine phosphate IV over 30 minutes once daily (QD) on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex vivo-expanded cord blood progenitor cells IV over 30 minutes on day 8.